| 产品描述: | PAI-1 抑制剂;PAI-1 Inhibitors;;InformationTM5441 TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines.TargetsPAI-1 (Cell-free assay) 9.7 μM |
| 靶点: |
IC50: 13.9~51.1 μM (Tumor cell lines) |
| 体内研究: |
向 HT1080 和 HCT116 异种移植小鼠口服 TM5441 (每天 20 mg/kg) 会增加肿瘤细胞凋亡,并对肿瘤血管系统产生显著破坏作用,这与肿瘤生长减少和存活率增加有关。口服给药后 1 小时平均血浆峰浓度为 11.4 μM,给药后 23 小时检测不到该水平。 TM5441 减轻 Nω-硝基-l-精氨酸甲酯诱导的心脏高血压和血管衰老,延长 klotho 缺失小鼠的寿命,并在癌症中引发抗肿瘤发生和抗血管生成活性。 |
| 参考文献: |
1. Placencio VR, et al. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. PLoS One. 2015 Jul 24;10(7):e0133786. 2. Jeong BY, et al. Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model. PLoS One. 2016 Jun 3;11(6):e0157012. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.332 ml |
11.66 ml |
23.32 ml |
| 5 mM |
0.466 ml |
2.332 ml |
4.664 ml |
| 10 mM |
0.233 ml |
1.166 ml |
2.332 ml |
| 50 mM |
0.047 ml |
0.233 ml |
0.466 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |